Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice

被引：38
|
作者：
Zhang, Mengling [1 ,2 ,3 ]
Sun, Jin [1 ]
Li, Min [1 ]
Jin, Xia [3 ]
机构：
[1] Chinese Acad Sci, Inst Pasteur Shanghai, Viral Dis & Vaccine Translat Res Unit, CAS Key Lab Mol Virol & Immunol, Shanghai, Peoples R China
[2] Univ Chinese Acad Sci, Beijing, Peoples R China
[3] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China
来源：
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT | 2020年 / 18卷
基金：
美国国家科学基金会; 国家重点研发计划;
关键词：
TETRAVALENT DENGUE VACCINE; NONSTRUCTURAL PROTEIN NS1; DNA VACCINE; VIRUS; EFFICACY; IMMUNITY; ENHANCEMENT; ANTIBODIES; INFLUENZA; RESPONSES;
D O I：
10.1016/j.omtm.2020.07.013
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Dengue virus (DENV) infection is a major global public health concern, and there is no effective vaccine for it. In this study, we describe the design and characterization of three nucleotide-modified mRNA vaccines (prME-mRNA, E80-mRNA, and NS1-mRNA) for DENV-2. Our results showed that vaccination with E80-mRNA alone or a combination of E80-mRNA and NS1-mRNA can induce high levels of neutralizing antibodies and antigen-specific T cell responses; furthermore, these vaccines confer complete protection against DENV-2 challenge in immunocompetent mice. These data provide foundations for further development of a tetravalent DENV vaccine based on nucleotide-modified mRNA.
引用
收藏
页码：702 / 712
页数：11
相关论文
共 50 条
  • [21] The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2
    Gil, Lazaro
    Marcos, Ernesto
    Izquierdo, Alienys
    Lazo, Laura
    Valdes, Iris
    Ambala, Penis
    Ochola, Lucy
    Hitler, Rikoi
    Suzarte, Edith
    Alvarez, Mayling
    Kimiti, Prisilla
    Ndung'u, James
    Kariuki, Thomas
    Guadalupe Guzman, Maria
    Guillen, Gerardo
    Hermida, Lisset
    IMMUNOLOGY AND CELL BIOLOGY, 2015, 93 (01): : 57 - 66
  • [22] A highly efficient needle-free-injection delivery system for mRNA-LNP vaccination against SARS-CoV-2
    Mao, Shanhong
    Li, Shiyou
    Zhang, Yuxin
    Long, Luoxin
    Peng, Junfeng
    Cao, Yuanyan
    Mao, Jessica Z.
    Qi, Xin
    Xin, Qi
    San, Guoliang
    Ding, Jing
    Jiang, Jun
    Bai, Xuejiao
    Wang, Qianting
    Xu, Pengfei
    Xia, Huan
    Lu, Lijun
    Xie, Liangzhi
    Kong, Desheng
    Zhu, Shuangli
    Xu, Wenbo
    NANO TODAY, 2023, 48
  • [23] DENV-3 precursor membrane (prM) glycoprotein enhances E protein immunogenicity and confers protection against DENV-2 infections in a murine model
    Dias, Roberto S.
    Teixeira, Michelle D.
    Xisto, Mariana F.
    Prates, John W. O.
    Da Silva, Jessica D.
    Mello, Iago O.
    Da Silva, Cynthia C.
    De Paula, Sergio O.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (05) : 1271 - 1277
  • [24] A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
    Carter, Brandon
    Huang, Pinghan
    Liu, Ge
    Liang, Yuejin
    Lin, Paulo J. C.
    Peng, Bi-Hung
    McKay, Lindsay G. A.
    Dimitrakakis, Alexander
    Hsu, Jason
    Tat, Vivian
    Saenkham-Huntsinger, Panatda
    Chen, Jinjin
    Kaseke, Clarety
    Gaiha, Gaurav D.
    Xu, Qiaobing
    Griffiths, Anthony
    Tam, Ying K.
    Tseng, Chien-Te K.
    Gifford, David K.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [25] A Trivalent HSV-2 gC2, gD2, gE2 Nucleoside-Modified mRNA-LNP Vaccine Provides Outstanding Protection in Mice against Genital and Non-Genital HSV-1 Infection, Comparable to the Same Antigens Derived from HSV-1
    Egan, Kevin P.
    Awasthi, Sita
    Tebaldi, Giulia
    Hook, Lauren M.
    Naughton, Alexis M.
    Fowler, Bernard T.
    Beattie, Mitchell
    Alameh, Mohamad-Gabriel
    Weissman, Drew
    Cohen, Gary H.
    Friedman, Harvey M.
    VIRUSES-BASEL, 2023, 15 (07):
  • [26] mRNA-LNP vaccine-induced CD8+T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies
    Montoya, Brian
    Melo-Silva, Carolina R.
    Tang, Lingjuan
    Kafle, Samita
    Lidskiy, Peter
    Bajusz, Csaba
    Vadovics, Mate
    Muramatsu, Hiromi
    Abraham, Edit
    Lipinszki, Zoltan
    Chatterjee, Debotri
    Scher, Gabrielle
    Benitez, Juliana
    Sung, Molly M. H.
    Tam, Ying K.
    Catanzaro, Nicholas J.
    Schaefer, Alexandra
    Andino, Raul
    Baric, Ralph S.
    Martinez, David R.
    Pardi, Norbert
    Sigal, Luis J.
    MOLECULAR THERAPY, 2024, 32 (06) : 1790 - 1804
  • [27] A SINGLE DOSE OF TV005 ELICITS COMPLETE PROTECTION AGAINST CHALLENGE WITH THE HETEROTYPIC DENV-2, RDEN2.30
    Durbin, Anna P.
    Kirkpatrick, Beth D.
    Tibery, Cecilia M.
    Grier, Palmtama
    Pierce, Kristen K.
    He, Helen
    Eby, Yolanda
    Carmolli, Marya P.
    Ventrone, Cassandra
    Diehl, Sean A.
    Whitehead, Stephen S.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 95 (05): : 19 - 19
  • [28] Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus
    Ye, Tianxi
    Zhou, Jinge
    Guo, Chen
    Zhang, Kaiyue
    Wang, Yuping
    Liu, Yanhui
    Zhou, Junhui
    Xie, Yalin
    Li, Entao
    Gong, Rui
    Zhang, Jiancun
    Chuai, Xia
    Chiu, Sandra
    CELL REPORTS, 2024, 43 (06):
  • [29] Two Novel Salmonella Bivalent Vaccines Confer Dual Protection against Two Salmonella Serovars in Mice
    Zhao, Xinxin
    Dai, Qinlong
    Jia, Renyong
    Zhu, Dekang
    Liu, Mafeng
    Wang, Mingshu
    Chen, Shun
    Sun, Kunfeng
    Yang, Qiao
    Wu, Ying
    Cheng, Anchun
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2017, 7
  • [30] The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines
    Ka, Samita
    Montoya, Brian
    Tang, Lingjuan
    Tam, Ying K.
    Muramatsu, Hiromi
    Pardi, Norbert
    Sigal, Luis J.
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (03):
12345